Rafferty Asset Management, LLC Point Biopharma Global Inc. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.67 - $9.71 $182,998 - $266,403	27,436 Added 14.02%	223,080 $1.49 Million
Q2 2023 Aug 11, 2023	BUY	$6.86 - $10.86 $170,875 - $270,511	24,909 Added 14.59%	195,644 $1.77 Million
Q1 2023 May 11, 2023	SELL	$6.78 - $8.1 $858,639 - $1.03 Million	-126,643 Reduced 42.59%	170,735 $1.24 Million
Q4 2022 Feb 13, 2023	BUY	$5.72 - $9.78 $851,147 - $1.46 Million	148,802 Added 100.15%	297,378 $2.17 Million
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $654,249 - $931,673	90,366 Added 155.24%	148,576 $1.15 Million
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $325,976 - $552,995	58,210 New	58,210 $396,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.